Clinical Trials
8 trialsNCT03358472 2025-12-03
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
Incyte Corporation
Phase 3 Completed
NCT02327078 2025-08-14
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Incyte Corporation
Phase 1/2 Completed
NCT02178722 2022-02-14
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
Incyte Corporation
Phase 1/2 Completed
NCT02318277 2022-01-13
A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)
Incyte Corporation
Phase 1/2 Completed
NCT03463161 2020-01-27
ORKA
University of Chicago
Phase 2 Terminated
NCT03342352 2019-12-20
Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)
Incyte Corporation
Phase 3 Withdrawn
NCT03325465 2019-04-22
Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck
University of Chicago
Phase 2 Withdrawn
NCT03238638 2018-01-04
A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
University of Chicago
Phase 2 Withdrawn